1191900-51-2

1191900-51-2 structure

Name: Brexpiprazole S-oxide
Chemical Name: DM-3411
CAS Number: 1191900-51-2
Molecular Formula: C₂₅H₂₇N₃O₃S
Molecular Weight: 449.565
Catalog: Signaling Pathways GPCR/G Protein 5-HT Receptor
Create Date: 2018-12-03 16:59:46
Modify Date: 2024-01-02 12:46:44
Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM[1][2][3].

Name	DM-3411
Synonyms	Benzo[b]thiophenium, 4-[4-[4-[(1,2-dihydro-2-oxo-7-quinolinyl)oxy]butyl]-1-piperazinyl]-1-hydroxy-, inner salt N22UPQ09R0 4-(4-{4-[(2-Oxo-1,2-dihydro-7-quinolinyl)oxy]butyl}-1-piperazinyl)-1-benzothiophenium-1-olate DM-3411 UNII:N22UPQ09R0 Brexpiprazole Sulfoxide Brexpiprazole S-Oxide Brexpiprazole Impurity 20

Description	Brexpiprazole S-oxide (DM-3411) is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM[1][2][3].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor
Target	Ki: 0.12 nM (5-HT1A), 0.3 nM (D2L), 0.47 nM (5-HT2A)[2]
References	[1]. Chen B, et al. Effects of 26 Recombinant CYP3A4 Variants on Brexpiprazole Metabolism. Chem Res Toxicol. 2019 Oct 17. [2]. Ishima T, et al. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors. Eur Neuropsychopharmacol. 2015 Apr;25(4):505-11. [3]. Yoshimi N, et al. Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator. Eur Neuropsychopharmacol. 2015 Mar;25(3):356-64.